Expert guidance on prenatal treatment and management for fetal arrhythmia
Fetal Heart Disease Cooperation Team of Pediatric Cardiovascular Group of Chinese Pediatric Society of Chinese Medial Association,Perinatal Congenital Heart Disease Cooperation Team of Pediatric Cardiovascular Group of Chinese Pediatric Society of Chinese Medial Association,Zhou Kaiyu,Chen Sun,Wang Chuan,Li Yifei,Pan Wei,Zhao Bowen,Zhang Yuqi,Pang Kunjing,Ding Wenhong,Ren Yunyun,Lin Jianhua,Han Bo,Lyu Haitao,Zhang Qingyou,Wu Yurong,Liu Baomin,Wu Lin,Zhang Yanmin,Xiao Tingting,He Yihua,Hua Yimin
DOI: https://doi.org/10.3877/cma.j.issn.1673-5250.2022.01.003
2022-01-01
Abstract:Fetal arrhythmias (FA) are common cardiac disorders in clinics of obstetrics and pediatric cardiology. Approximately 10% FA could persist or even progress, which may result in secondary organ injury, such as fetal heart failure, fetal premature delivery or even fetal demise. Based on accurate prenatal diagnosis of FA, reasonable classification and timely intervention for severely affected fetuses could improve prognosis of FA, which has great medical and sociological significance. Despite much progress have been achieved in field of prenatal management of FA in foreign countries, there are a few relevant studies in China. Moreover, there are great differences in prenatal management strategies for FA among different medical centers. In order to improve understanding of perinatal management of FA for obstetricians and pediatricians, standardize the intervention indications and treatment strategies, and promote the benign development of prenatal intervention for FA in China, experts from the Fetal and Perinatal Heart Disease Cooperation Team of Pediatric Cardiovascular Group of Chinese Pediatric Society, Chinese Medial Association put forward the Expert Guidance on Prenatal Treatment and Management for Fetal Arrhythmia after full discussion on prenatal intervention indications, treatment strategies as well as details of medicines selections according to the latest research progresses and current domestic situations. However, relevant clinical studies are limited to single-center, retrospective, and small sample size studies and the conclusions differed among different studies. Furthermore, only a minority of data were from China. Therefore, the evidences level are not so high. With further development of prenatal intervention for FA, the release of data from several multiple-centers, prospective and randomized controlled clinical studies, and with joint efforts of domestic clinicians, the content of this guidance will continue to be update and improved, and it will also be more in line with the actual domestic clinical practice needs, to achieve the goal of promoting continuous improvement of prenatal treatment and management of FA.